PRVB: Major Risks Retired, Major Upside Ahead

PRVB: Major Risks Retired, Major Upside Ahead

Shares of Provention Bio (PRVB) have staged an impressive rally since announcing game-changing data on teplizumab for the treatment of patients at-risk of developing Type 1 Diabetes. But there’s plenty more upside ahead. Here’s why…